Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPd for Systemic AL Amyloidosis
NCT06342466Phase 2Recruiting
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pomalidomide in systemic light chain amyloidosis. Primary endpoint: Hematologic Very Good Partial Response and Complete Response Rate at 6 months. Started May 2024; status: recruiting.
02
Drugs
pomalidomide
03
Conditions
systemic light chain amyloidosis
Beyond the preview
Go deeper on NCT06342466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06342466.